RxDoctor Payments Data

Ryan Pulham, NP

Nurse Practitioner · Provo, UTNPI 1437811585

Payments from drug & device makers

$2,769in general payments, 2019–2025

Across 160 payments — averaging $17.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$725
  • Lilly USA, LLC$365
  • Novo Nordisk$180
  • GSK$150
  • Alkermes, Inc.$136
  • Johnson & Johnson$122
  • plus $1K from 28 others

What the payments were for

  • Food & beverage$2,769100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,769 in reported general payments places this provider in the 90th percentile of 979 nurse practitioner providers in Utah.

See all nurse practitioner providers in Utah

Medicare billing

Part B allowed, 2024
$40,644
Medicare patients
160
Services billed
1,633

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide39$50,733
MounjaroTirzepatide23$24,407
JardianceEmpagliflozin20$23,929
EliquisApixaban23$19,608
FarxigaDapagliflozin Propanediol11$14,141
OzempicSemaglutide12$13,594
Rosuvastatin Calcium107$1,924
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,549
Levothyroxine Sodium116$1,527
Omeprazole94$1,518
Celecoxib21$1,159
Pregabalin21$1,045
Albuterol Sulfate HfaAlbuterol Sulfate29$947
Atorvastatin Calcium97$944
Lisinopril114$922

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$365$75,14062 claims
Boehringer IngelheimJardiance$90$23,92920 claims
PfizerEliquis$101$19,60823 claims
AstraZenecaFarxiga$48$14,14111 claims
Novo NordiskOzempic$180$13,59412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 979 nurse practitioner providers in Utah.

Other nurse practitioner in Provo

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →